Efficacy of Dr. SKS hair booster serum for the treatment of hair loss in COVID-19 induced persistent telogen effluvium
DOI:
https://doi.org/10.18203/2320-6012.ijrms20240837Keywords:
COVID-19, Dr. SKS hair booster serum, Hair loss, Telogen effluviumAbstract
Background: Excessive hair shedding occurs in patients with coronavirus disease 2019 induced telogen effluvium. Dr. SKS hair booster serum has demonstrated encouraging benefits in different types of alopecia in previous studies. We sought to evaluate the efficacy of Dr. SKS hair booster serum for the treatment of COVID-19 induced persistent TE.
Methods: A total of 500 patients aged 18 to 60 years who had recovered from reverse transcription-polymerase chain reaction proven COVID-19 infection but experienced sustained hair fall even after 6 months were included in the study. One millilitre of Dr. SKS hair booster serum injection was administered intradermally in scalp per session. Efficacy and safety outcomes were evaluated at baseline, 3 and 6 months after the treatment.
Results: Approximately half of the patients demonstrated excellent improvement in expert panel global photographic assessment at 3 months (vertex area; 43.6% and frontal area; 46%) that was increased at 6 months (vertex area; 48% and frontal area; 50%). Each patient's clinical condition improved. All patients were satisfied with the results in terms of mean total hair growth satisfaction scale score of five aspects at 3 and 6 months treatment.
Conclusions: Intradermal injection of Dr. SKS hair booster serum proves to be effective treatment for hair loss in COVID-19-induced persistent TE.
References
Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium. Ir J Med Sci. 2022;191(4):1677-81.
Starace M, Iorizzo M, Sechi A, Alessandrini AM, Carpanese M, Bruni F, et al. Trichodynia and telogen effluvium in COVID-19 patients: results of an international expert opinion survey on diagnosis and management. JAAD Int. 2021;5:11-8.
Aksoy H, Yıldırım UM, Ergen P, Gürel MS. COVID-19 induced telogen effluvium. Dermatol Ther. 2021;34(6):e15175.
Rizzetto G, Diotallevi F, Campanati A, Radi G, Bianchelli T, Molinelli E, et al. Telogen effluvium related to post severe Sars-Cov-2 infection: clinical aspects and our management experience. Dermatol Ther. 2021;34(1):e14547.
Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH, Diab N, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20(3):395-407.
Moreno-Arrones OM, Lobato-Berezo A, Gomez-Zubiaur A, Arias-Santiago S, Saceda-Corralo D, Bernardez-Guerra C, et al. SARS-CoV-2-induced telogen effluvium: a multicentric study. J Eur Acad Dermatol Venereol. 2021;35(3):e181-3.
Mieczkowska K, Deutsch A, Borok J, Guzman AK, Fruchter R, Patel P, et al. Telogen effluvium: a sequela of COVID-19. Int J Dermatol. 2021;60(1): 122-4.
Mysore V, Parthasaradhi A, Kharkar RD, Ghoshal AK, Ganjoo A, Ravichandran G, et al. Expert consensus on the management of telogen Effluvium in India. Int J Trichology. 2019;11(3):107-12.
Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen effluvium: a review of the literature. Cureus. 2020;12(5):e8320.
Khare S. The efficacy and safety of Dr. SKS Hair Booster Serum (a cocktail of micronutrients and multivitamins) in adult males and females with androgenetic alopecia: an open-label, non-randomized, prospective study. Cureus. 2023;15(4): e37424.
Khare S. Efficacy of Dr. SKS Hair Booster Serum in the treatment of female pattern alopecia in patients with PCOS: an open-label, non-randomized, prospective study. Cureus. 2023;15(9):e44941.
Di Landro A, Naldi L, Glaser E, Paus R, Tosti A. Pathobiology questions raised by telogen effluvium and trichodynia in COVID‐19 patients. Exp Dermatol. 2021;30(7):999-1000.
Ito T, Ito N, Saathoff M, Bettermann A, Takigawa M, Paus R. Interferon-gamma is a potent inducer of catagen‐like changes in cultured human anagen hair follicles. Br J Dermatol. 2005;152(4):623-31.
Abrantes TF, Artounian KA, Falsey R, Simão JCL, Vañó-Galván S, Ferreira SB, et al. Time of onset and duration of post‐COVID‐19 acute telogen effluvium. J Am Acad Dermatol. 2021;85(4):975-6.
Olds H, Liu J, Luk K, Lim HW, Ozog D, Rambhatla PV. Telogen effluvium associated with COVID‐19 infection. Dermatol Ther. 2021;34(2):e14761.
Starace M, Iorizzo M, Sechi A, Alessandrini AM, Carpanese M, Bruni F, et al. Trichodynia and telogen effluvium in COVID‐19 patients results of an international expert opinion survey on diagnosis and management. JAAD Int. 2021;5:11-8.
Olds H, Liu J, Luk K, Lim HW, Ozog D, Rambhatla PV. Telogen effluvium associated with COVID-19 infection. Dermatol Ther. 2021;34(2):e14761.
Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH, Diab N, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20(3):395-407.
Rahman F, Akhter QS. Serum zinc and copper levels in alopecia. J Bangladesh Soc Physiol. 2019;14(1):21-5.
Lee SY, Nam KS, Seo YW, Lee JS, Chung H. Analysis of serum zinc and copper levels in alopecia areata. Ann Dermatol. 1997;9(4):239-41.
Bissett DL, Oblong JE, Berge CA. Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol Surg. 2005;31(2):860-5.
Watanabe Y, Nagashima T, Hanzawa N, Ishino A, Nakazawa Y, Ogo M, et al. Topical adenosine increases thick hair ratio in Japanese men with androgenetic alopecia. Int J Cosmet Sci. 2015;37(6): 579-87.
Sionkowska A, Kaczmarek B, Michalska M, Lewandowska K, Grabska S. Preparation and characterization of collagen/chitosan/hyaluronic acid thin films for application in hair care cosmetics. Pure Appl Chem. 2017;89(12):1829-39.
Zhang J, Ma X, Fan D, Zhu C, Deng J, Hui J, et al. Synthesis and characterization of hyaluronic acid/human-like collagen hydrogels. Mater Sci Eng Mater Biol Appl. 2014;43:547-54.
Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012; 2012:530121.
Mahabadi N, Bhusal A, Banks SW. Riboflavin deficiency. Treasure Island, FL: Stat Pearls Publishing; 2022.
Park SY, Na SY, Kim JH, Cho S, Lee JH. Iron plays a certain role in patterned hair loss. J Korean Med Sci. 2013;28(6):934-8.
Boccaletti V, Zendri E, Giordano G, Gnetti L, De Panfilis G. Familial uncombable hair syndrome: ultrastructural hair study and response to biotin. Pediatr Dermatol. 2007;24(3):14-6.
Shelley WB, Shelley ED. Uncombable hair syndrome: observations on response to biotin and occurrence in siblings with ectodermal dysplasia. J Am Acad Dermatol. 1985;13(1):97-102.
Trüeb RM. Serum biotin levels in women complaining of hair loss. Int J Trichol. 2016;8(2):73-7.
